Published

EE127 A REVIEW OF HEALTH ECONOMIC ANALYSES OF PSILOCYBIN, MIDOMAFETAMINE(MDMA), AND KETAMINE-BASED TREATMENTS FOR MENTAL HEALTH CARE

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Value in Health
Date: 2026-06-01
Source: Crossref
DOI: 10.1016/j.jval.2026.03.422
PubMed: Unavailable

Authors

Sidovar Matthew O'Connor Shane J.Orsini Lucinda

Watch author

Derived topics and classifications

psilocybin Review Article Review Article

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

EE127 A REVIEW OF HEALTH ECONOMIC ANALYSES OF PSILOCYBIN, MIDOMAFETAMINE(MDMA), AND KETAMINE-BASED TREATMENTS FOR MENTAL HEALTH CARE2026-06-01

Related papers

Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-02 From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical PracticePharmacology Research & Perspectives · 2026-05-10 Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health careTranslational Psychiatry · 2026-06-23 Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overviewJournal of Psychedelic Studies · 2026-07-13 Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARASAIMSARA Journal · 2026-06-15 Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USAAJPM Focus · 2026-05-01 Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12